December 27, 2006
Re "The myth of the big bad drug companies," Opinion, Dec. 22 Thank goodness someone has finally come to the defense of those victimized, abused and overregulated pharmaceutical goliaths. It makes sense that Richard Epstein, a consultant for the drug industry, should be the one to do it. I look forward to his next piece in which he'll explain how necessary it was for those giant companies to threaten to cut off supplies to Canadian pharmacies that sell their cheaper pills to American consumers.
February 2, 2012
Mitt versus Newt Re "Florida win won't seal race," Feb. 1 Why is Mitt Romney smiling in your front-page photograph? In order to win Florida, he apparently had to lavishly outspend the thrice-married ex-House speaker whose second wife recently went public with new details of his adultery with the lady who succeeded her. Romney's may be a victory, but it's pyrrhic at best and does not speak well for his ability to prevail going...
October 23, 1996 |
Major drug companies on Tuesday reported generally stronger-than-expected earnings, led by Eli Lilly, which showed continued gains in sales of the antidepressant Prozac. If last year's profit from Indianapolis-based Lilly's medical devices unit, which has been spun off, is excluded, the company's net income would have improved 33%. The company earned $415.6 million, or 76 cents per share, during the period ended Sept. 30, compared with $1.23 billion, or $2.14 share, during the 1995 quarter.
January 29, 1997 |
Speedy government approval of new drugs, rising demand from HMOs and stable or increasing prices are all helping the pharmaceutical industry post double-digit profit increases. Of nine major U.S. drug makers that have reported fourth-quarter earnings this month, the average gain is 20%. Merck & Co., American Home Products Corp. and Warner-Lambert Co. all beat analyst predictions with their reports Tuesday. Merck, based in Whitehouse Station, N.J., boosted net earnings 22% to $1.
January 15, 2001 |
A group of more than 40 drug companies is taking the South African government to court in a bid to stop the uncontrolled importation or manufacture of cut-price versions of patented AIDS drugs, officials said. The action, brought by the South African pharmaceutical manufacturers association on behalf of its members, will be heard in the Pretoria High Court on March 5, bringing to a head a three-year intellectual property dispute.
October 22, 1997 |
Prominent drug companies are making a last-minute push in Congress to forestall cheaper generic versions of some popular medicines that bring them hundreds of millions of dollars. The drug companies, led by New Jersey-based Bristol-Myers Squibb, are proposing to pay the government to extend their market monopolies on best-selling brand-name drugs such as the cancer treatment Taxol and the allergy medicine Claritin.